<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00001262</url>
  </required_header>
  <id_info>
    <org_study_id>900149</org_study_id>
    <secondary_id>90-CH-0149</secondary_id>
    <nct_id>NCT00001262</nct_id>
  </id_info>
  <brief_title>Copper Histidine Therapy for Menkes Diseases</brief_title>
  <official_title>Early Copper Histidine Therapy in Menkes Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Menkes Disease is a genetic disorder affecting the metabolism of copper. Patient with this
      disease are both physically and mentally retarded. Menkes disease is usually first detected
      in the first 2-3 months of life. Infant males born with the disease fail to thrive,
      experience hypothermia, have delayed development, and experience seizures. These infants also
      have characteristic physical features such as changes of their hair and face. Females may
      also have changes in hair and skin color, but rarely have significant medical problems.

      Appropriate treatment of Menkes Disease requires that the disease be diagnosed early and
      treatment started before irreversible brain damage occurs. The aim of treatment is to bypass
      the normal route of absorption of copper through the gastrointestinal tract. Copper must then
      be delivered to brain cells and be available for use by enzymes.

      Copper histidine is a copper replacement that can be injected directly into the body to avoid
      absorption through the gastrointestinal tract. However, studies have shown the genetic
      abnormalities causing Menkes disease cannot simply be corrected by copper replacement
      injections.

      The genetic abnormality causing Menkes disease can vary in its severity. Patients with a
      genetic abnormality that may still permit some production of the enzymes required to process
      copper may receive benefit from early treatment with copper replacement. However, patients
      with severe abnormalities of the genes responsible for copper metabolism may receive no
      benefit from copper replacement.

      The purpose of this study is to continue to evaluate the effects of early copper histidine in
      Menkes disease patients and to correlate specific molecular defects with responses to
      treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Menkes disease is an X-linked recessive neurodegenerative disorder caused by defects in a
      gene that encodes an evolutionarily conserved copper-transporting ATPase (ATP7A). Several
      issues must be addressed in configuring therapeutic strategies for this disorder: (a)
      affected infants must be identified and treatment commenced very early in life before
      irreparable neurodegeneration occurs, (b) the block in intestinal absorption of copper must
      be bypassed, (c) circulating copper must be delivered to the brain, and (d) copper must be
      available to enzymes within cells that require it as a cofactor.

      Very early, pre-symptomatic therapy with copper injections has been associated with improved
      overall survival and, in some patients - based on their molecular defects, with vastly better
      neurological outcomes in comparison to the usual natural history of this disorder. The
      purpose of this study is to continue to provide early copper treatment to other newborn
      infants diagnosed as having Menkes disease.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 1990</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gross Motor Development at 36 Mos of Age or at Death (Mos)</measure>
    <time_frame>36 months or death</time_frame>
    <description>This was measured based on the Denver Developmental Screening Test (DDST) I or II for age-appropriate gross motor development in apparently normal healthy subjects at specific ages (in months). The DDST employs a grid to assess expected developmental milestones in relation to chronologic age.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fine Motor Adaptive Development at 36 Mos of Age or at Death (Mos)</measure>
    <time_frame>36 months or death</time_frame>
    <description>This was measured based on the Denver Developmental Screening Test (DDST) I or II for age-appropriate fine motor development in apparently normal healthy subjects at specific ages (in months). The DDST employs a grid to assess expected developmental milestones in relation to chronologic age.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Personal-Social Development at 36 Mos of Age or at Death (Mos)</measure>
    <time_frame>36 months or death</time_frame>
    <description>This was measured based on the Denver Developmental Screening Test (DDST) I or II for age-appropriate personal-social development in apparently normal healthy subjects at specific ages (in months). The DDST employs a grid to assess expected developmental milestones in relation to chronologic age.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Language Development at 36 Mos of Age or at Death (Mos)</measure>
    <time_frame>36 months or death</time_frame>
    <description>This was measured based on the Denver Developmental Screening Test (DDST) I or II for age-appropriate language development in apparently normal healthy subjects at specific ages (in months). The DDST employs a grid to assess expected developmental milestones in relation to chronologic age.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Somatic Growth Percentiles at 3 Years of Age (or at Age of Death) - Weight Percentile</measure>
    <time_frame>36 months or death</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Somatic Growth Percentiles at 3 Years of Age (or at Age of Death) - Length Percentile</measure>
    <time_frame>36 months or death</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Somatic Growth Percentiles at 3 Years of Age (or at Age of Death) - Head Circumference Percentile</measure>
    <time_frame>36 months or death</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Kinky Hair Syndrome</condition>
  <arm_group>
    <arm_group_label>Copper histidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Copper Histidine</intervention_name>
    <arm_group_label>Copper histidine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

        Newborn infants in whom Menkes disease is confirmed on biochemical or molecular grounds and
        in whom no neurological symptoms are present are eligible for enrollment in this study.

        EXCLUSION CRITERIA:

        Newly identified patients classified as symptomatic at the time of diagnosis, and affected
        individuals with mild phenotypes are not currently eligible for this clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen G Kaler, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_1990-CH-0149.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <results_reference>
    <citation>Kaler SG, Buist NR, Holmes CS, Goldstein DS, Miller RC, Gahl WA. Early copper therapy in classic Menkes disease patients with a novel splicing mutation. Ann Neurol. 1995 Dec;38(6):921-8.</citation>
    <PMID>8526465</PMID>
  </results_reference>
  <results_reference>
    <citation>Kaler SG, Holmes CS, Goldstein DS, Tang J, Godwin SC, Donsante A, Liew CJ, Sato S, Patronas N. Neonatal diagnosis and treatment of Menkes disease. N Engl J Med. 2008 Feb 7;358(6):605-14. doi: 10.1056/NEJMoa070613.</citation>
    <PMID>18256395</PMID>
  </results_reference>
  <results_reference>
    <citation>Kaler SG, Gahl WA, Berry SA, Holmes CS, Goldstein DS. Predictive value of plasma catecholamine levels in neonatal detection of Menkes disease. J Inherit Metab Dis. 1993;16(5):907-8.</citation>
    <PMID>8295415</PMID>
  </results_reference>
  <results_reference>
    <citation>Kaler SG, Westman JA, Bernes SM, Elsayed AM, Bowe CM, Freeman KL, Wu CD, Wallach MT. Gastrointestinal hemorrhage associated with gastric polyps in Menkes disease. J Pediatr. 1993 Jan;122(1):93-5.</citation>
    <PMID>8419622</PMID>
  </results_reference>
  <results_reference>
    <citation>Grange DK, Kaler SG, Albers GM, Petterchak JA, Thorpe CM, DeMello DE. Severe bilateral panlobular emphysema and pulmonary arterial hypoplasia: unusual manifestations of Menkes disease. Am J Med Genet A. 2005 Dec 1;139A(2):151-5.</citation>
    <PMID>16278898</PMID>
  </results_reference>
  <results_reference>
    <citation>Price DJ, Ravindranath T, Kaler SG. Internal jugular phlebectasia in Menkes disease. Int J Pediatr Otorhinolaryngol. 2007 Jul;71(7):1145-8. Epub 2007 May 4.</citation>
    <PMID>17482283</PMID>
  </results_reference>
  <results_reference>
    <citation>Hicks JD, Donsante A, Pierson TM, Gillespie MJ, Chou DE, Kaler SG. Increased frequency of congenital heart defects in Menkes disease. Clin Dysmorphol. 2012 Apr;21(2):59-63. doi: 10.1097/MCD.0b013e32834ea52b.</citation>
    <PMID>22134099</PMID>
  </results_reference>
  <results_reference>
    <citation>Kaler SG, Gallo LK, Proud VK, Percy AK, Mark Y, Segal NA, Goldstein DS, Holmes CS, Gahl WA. Occipital horn syndrome and a mild Menkes phenotype associated with splice site mutations at the MNK locus. Nat Genet. 1994 Oct;8(2):195-202.</citation>
    <PMID>7842019</PMID>
  </results_reference>
  <results_reference>
    <citation>Liu PC, Chen YW, Centeno JA, Quezado M, Lem K, Kaler SG. Downregulation of myelination, energy, and translational genes in Menkes disease brain. Mol Genet Metab. 2005 Aug;85(4):291-300.</citation>
    <PMID>15923132</PMID>
  </results_reference>
  <results_reference>
    <citation>Kaler SG, Das S, Levinson B, Goldstein DS, Holmes CS, Patronas NJ, Packman S, Gahl WA. Successful early copper therapy in Menkes disease associated with a mutant transcript containing a small In-frame deletion. Biochem Mol Med. 1996 Feb;57(1):37-46.</citation>
    <PMID>8812725</PMID>
  </results_reference>
  <results_reference>
    <citation>Tang J, Donsante A, Desai V, Patronas N, Kaler SG. Clinical outcomes in Menkes disease patients with a copper-responsive ATP7A mutation, G727R. Mol Genet Metab. 2008 Nov;95(3):174-81. doi: 10.1016/j.ymgme.2008.06.015. Epub 2008 Aug 26.</citation>
    <PMID>18752978</PMID>
  </results_reference>
  <results_reference>
    <citation>Kaler SG, Tang J, Donsante A, Kaneski CR. Translational read-through of a nonsense mutation in ATP7A impacts treatment outcome in Menkes disease. Ann Neurol. 2009 Jan;65(1):108-13. doi: 10.1002/ana.21576.</citation>
    <PMID>19194885</PMID>
  </results_reference>
  <results_reference>
    <citation>Kaler SG, Liew CJ, Donsante A, Hicks JD, Sato S, Greenfield JC. Molecular correlates of epilepsy in early diagnosed and treated Menkes disease. J Inherit Metab Dis. 2010 Oct;33(5):583-9. doi: 10.1007/s10545-010-9118-2. Epub 2010 Jul 21.</citation>
    <PMID>20652413</PMID>
  </results_reference>
  <results_reference>
    <citation>Desai V, Donsante A, Swoboda KJ, Martensen M, Thompson J, Kaler SG. Favorably skewed X-inactivation accounts for neurological sparing in female carriers of Menkes disease. Clin Genet. 2011 Feb;79(2):176-82. doi: 10.1111/j.1399-0004.2010.01451.x.</citation>
    <PMID>20497190</PMID>
  </results_reference>
  <results_reference>
    <citation>Kaler SG. Neurodevelopment and brain growth in classic Menkes disease is influenced by age and symptomatology at initiation of copper treatment. J Trace Elem Med Biol. 2014 Oct;28(4):427-30. doi: 10.1016/j.jtemb.2014.08.008. Epub 2014 Aug 28.</citation>
    <PMID>25281031</PMID>
  </results_reference>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 1999</study_first_submitted>
  <study_first_submitted_qc>November 3, 1999</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 1999</study_first_posted>
  <results_first_submitted>August 5, 2014</results_first_submitted>
  <results_first_submitted_qc>September 29, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 30, 2015</results_first_posted>
  <last_update_submitted>September 29, 2015</last_update_submitted>
  <last_update_submitted_qc>September 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Menkes</keyword>
  <keyword>Copper</keyword>
  <keyword>X-Linked</keyword>
  <keyword>Neurodegeneration</keyword>
  <keyword>ATP7A</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Menkes Kinky Hair Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Copper</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Early</title>
          <description>Classic Menkes disease: Copper histidine treatment beginning within 1 month of age</description>
        </group>
        <group group_id="P2">
          <title>Late</title>
          <description>Classic Menkes disease: Copper histidine treatment beginning after 1 month of age and after onset of symptoms</description>
        </group>
        <group group_id="P3">
          <title>Mild</title>
          <description>Milder variants of Menkes disease: Copper histidine treatment beginning late (L) and after onset of (milder) symptoms</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Early</title>
          <description>Classic Menkes disease: Copper histidine treatment beginning within 1 month of age</description>
        </group>
        <group group_id="B2">
          <title>Late</title>
          <description>Classic Menkes disease: Copper histidine treatment beginning after 1 month of age and after onset of symptoms</description>
        </group>
        <group group_id="B3">
          <title>Mild</title>
          <description>Milder variants of Menkes disease: Copper histidine treatment beginning late (L) and after onset of (milder) symptoms</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="35"/>
            <count group_id="B2" value="22"/>
            <count group_id="B3" value="3"/>
            <count group_id="B4" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Gross Motor Development at 36 Mos of Age or at Death (Mos)</title>
        <description>This was measured based on the Denver Developmental Screening Test (DDST) I or II for age-appropriate gross motor development in apparently normal healthy subjects at specific ages (in months). The DDST employs a grid to assess expected developmental milestones in relation to chronologic age.</description>
        <time_frame>36 months or death</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Early</title>
            <description>Classic Menkes disease: Copper histidine treatment beginning within 1 month of age</description>
          </group>
          <group group_id="O2">
            <title>Late</title>
            <description>Classic Menkes disease: Copper histidine treatment beginning after 1 month of age and after onset of symptoms</description>
          </group>
          <group group_id="O3">
            <title>Mild</title>
            <description>Milder variants of Menkes disease: Copper histidine treatment beginning late (L) and after onset of (milder) symptoms</description>
          </group>
        </group_list>
        <measure>
          <title>Gross Motor Development at 36 Mos of Age or at Death (Mos)</title>
          <description>This was measured based on the Denver Developmental Screening Test (DDST) I or II for age-appropriate gross motor development in apparently normal healthy subjects at specific ages (in months). The DDST employs a grid to assess expected developmental milestones in relation to chronologic age.</description>
          <units>Other - months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.743" spread="12.200"/>
                    <measurement group_id="O2" value="2.455" spread="2.154"/>
                    <measurement group_id="O3" value="15.667" spread="9.815"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Fine Motor Adaptive Development at 36 Mos of Age or at Death (Mos)</title>
        <description>This was measured based on the Denver Developmental Screening Test (DDST) I or II for age-appropriate fine motor development in apparently normal healthy subjects at specific ages (in months). The DDST employs a grid to assess expected developmental milestones in relation to chronologic age.</description>
        <time_frame>36 months or death</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Early</title>
            <description>Classic Menkes disease: Copper histidine treatment beginning within 1 month of age</description>
          </group>
          <group group_id="O2">
            <title>Late</title>
            <description>Classic Menkes disease: Copper histidine treatment beginning after 1 month of age and after onset of symptoms</description>
          </group>
          <group group_id="O3">
            <title>Mild</title>
            <description>Milder variants of Menkes disease: Copper histidine treatment beginning late (L) and after onset of (milder) symptoms</description>
          </group>
        </group_list>
        <measure>
          <title>Fine Motor Adaptive Development at 36 Mos of Age or at Death (Mos)</title>
          <description>This was measured based on the Denver Developmental Screening Test (DDST) I or II for age-appropriate fine motor development in apparently normal healthy subjects at specific ages (in months). The DDST employs a grid to assess expected developmental milestones in relation to chronologic age.</description>
          <units>Other - Months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.200" spread="12.762"/>
                    <measurement group_id="O2" value="2.409" spread="1.652"/>
                    <measurement group_id="O3" value="17.667" spread="13.204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Personal-Social Development at 36 Mos of Age or at Death (Mos)</title>
        <description>This was measured based on the Denver Developmental Screening Test (DDST) I or II for age-appropriate personal-social development in apparently normal healthy subjects at specific ages (in months). The DDST employs a grid to assess expected developmental milestones in relation to chronologic age.</description>
        <time_frame>36 months or death</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Early</title>
            <description>Classic Menkes disease: Copper histidine treatment beginning within 1 month of age</description>
          </group>
          <group group_id="O2">
            <title>Late</title>
            <description>Classic Menkes disease: Copper histidine treatment beginning after 1 month of age and after onset of symptoms</description>
          </group>
          <group group_id="O3">
            <title>Mild</title>
            <description>Milder variants of Menkes disease: Copper histidine treatment beginning late (L) and after onset of (milder) symptoms</description>
          </group>
        </group_list>
        <measure>
          <title>Personal-Social Development at 36 Mos of Age or at Death (Mos)</title>
          <description>This was measured based on the Denver Developmental Screening Test (DDST) I or II for age-appropriate personal-social development in apparently normal healthy subjects at specific ages (in months). The DDST employs a grid to assess expected developmental milestones in relation to chronologic age.</description>
          <units>Other - Months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.657" spread="13.482"/>
                    <measurement group_id="O2" value="3.364" spread="3.499"/>
                    <measurement group_id="O3" value="17.667" spread="15.308"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Language Development at 36 Mos of Age or at Death (Mos)</title>
        <description>This was measured based on the Denver Developmental Screening Test (DDST) I or II for age-appropriate language development in apparently normal healthy subjects at specific ages (in months). The DDST employs a grid to assess expected developmental milestones in relation to chronologic age.</description>
        <time_frame>36 months or death</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Early</title>
            <description>Classic Menkes disease: Copper histidine treatment beginning within 1 month of age</description>
          </group>
          <group group_id="O2">
            <title>Late</title>
            <description>Classic Menkes disease: Copper histidine treatment beginning after 1 month of age and after onset of symptoms</description>
          </group>
          <group group_id="O3">
            <title>Mild</title>
            <description>Milder variants of Menkes disease: Copper histidine treatment beginning late (L) and after onset of (milder) symptoms</description>
          </group>
        </group_list>
        <measure>
          <title>Language Development at 36 Mos of Age or at Death (Mos)</title>
          <description>This was measured based on the Denver Developmental Screening Test (DDST) I or II for age-appropriate language development in apparently normal healthy subjects at specific ages (in months). The DDST employs a grid to assess expected developmental milestones in relation to chronologic age.</description>
          <units>Other - Months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.800" spread="12.034"/>
                    <measurement group_id="O2" value="3.227" spread="2.943"/>
                    <measurement group_id="O3" value="21.000" spread="9.539"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Somatic Growth Percentiles at 3 Years of Age (or at Age of Death) - Weight Percentile</title>
        <time_frame>36 months or death</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Early</title>
            <description>Classic Menkes disease: Copper histidine treatment beginning within 1 month of age</description>
          </group>
          <group group_id="O2">
            <title>Late</title>
            <description>Classic Menkes disease: Copper histidine treatment beginning after 1 month of age and after onset of symptoms</description>
          </group>
          <group group_id="O3">
            <title>Mild</title>
            <description>Milder variants of Menkes disease: Copper histidine treatment beginning late (L) and after onset of (milder) symptoms</description>
          </group>
        </group_list>
        <measure>
          <title>Somatic Growth Percentiles at 3 Years of Age (or at Age of Death) - Weight Percentile</title>
          <units>Other - Percentile</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.086" spread="19.589"/>
                    <measurement group_id="O2" value="11.273" spread="17.097"/>
                    <measurement group_id="O3" value="5.000" spread="8.660"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Somatic Growth Percentiles at 3 Years of Age (or at Age of Death) - Length Percentile</title>
        <time_frame>36 months or death</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Early</title>
            <description>Classic Menkes disease: Copper histidine treatment beginning within 1 month of age</description>
          </group>
          <group group_id="O2">
            <title>Late</title>
            <description>Classic Menkes disease: Copper histidine treatment beginning after 1 month of age and after onset of symptoms</description>
          </group>
          <group group_id="O3">
            <title>Mild</title>
            <description>Milder variants of Menkes disease: Copper histidine treatment beginning late (L) and after onset of (milder) symptoms</description>
          </group>
        </group_list>
        <measure>
          <title>Somatic Growth Percentiles at 3 Years of Age (or at Age of Death) - Length Percentile</title>
          <units>Other - Percentile</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.286" spread="13.501"/>
                    <measurement group_id="O2" value="15.455" spread="23.192"/>
                    <measurement group_id="O3" value="28.333" spread="40.723"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Somatic Growth Percentiles at 3 Years of Age (or at Age of Death) - Head Circumference Percentile</title>
        <time_frame>36 months or death</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Early</title>
            <description>Classic Menkes disease: Copper histidine treatment beginning within 1 month of age</description>
          </group>
          <group group_id="O2">
            <title>Late</title>
            <description>Classic Menkes disease: Copper histidine treatment beginning after 1 month of age and after onset of symptoms</description>
          </group>
          <group group_id="O3">
            <title>Mild</title>
            <description>Milder variants of Menkes disease: Copper histidine treatment beginning late (L) and after onset of (milder) symptoms</description>
          </group>
        </group_list>
        <measure>
          <title>Somatic Growth Percentiles at 3 Years of Age (or at Age of Death) - Head Circumference Percentile</title>
          <units>Other - Percentile</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.286" spread="27.060"/>
                    <measurement group_id="O2" value="11.136" spread="14.551"/>
                    <measurement group_id="O3" value="18.333" spread="27.538"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>36 months or death</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Early</title>
          <description>Classic Menkes disease: Copper histidine treatment beginning within 1 month of age</description>
        </group>
        <group group_id="E2">
          <title>Late</title>
          <description>Classic Menkes disease: Copper histidine treatment beginning after 1 month of age and after onset of symptoms</description>
        </group>
        <group group_id="E3">
          <title>Mild</title>
          <description>Milder variants of Menkes disease: Copper histidine treatment beginning late (L) and after onset of (milder) symptoms</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>Menkes disease</description>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="35"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="22"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kaler, Stephen G</name_or_title>
      <organization>National Institute of Child Health and Human Development</organization>
      <phone>+1 301 451 6034</phone>
      <email>kalers@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

